Thyrocare Technologies Limited announced the outcome of its Board Meeting held on May 7, 2026. The Board recommended a final dividend of ₹7.00 per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). This, combined with the interim dividend of ₹7.00 per equity share (pre-bonus adjustment), brings the total dividend for FY26 to ₹9.33 per equity share (post-bonus adjustment). The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a five-year term, commencing from the conclusion of the 26th AGM (2026) until the 31st AGM (2031), replacing M/s. M S K A & Associates LLP. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for the financial year 2026-27. Key leadership changes were approved, including the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director & CEO for another five-year term from May 4, 2027, to May 3, 2032. Additionally, Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 8, 2026. The Board also noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, Non-Executive, Non-Independent Directors, effective May 7, 2026. Furthermore, the Board approved an investment of up to ₹5.50 crore in the equity shares of its wholly-owned subsidiary, Think Health Diagnostics Private Limited, to support its operations and capital expenditure. The Memorandum of Association (MOA) of the Company will also be altered to align with the Companies Act, 2013, and broaden the scope of its business activities within the healthcare and diagnostics ecosystem. The Board Meeting commenced at 3:35 PM and concluded at 5:40 PM.
